title: Suppression of multidrug-resistant HIV-1 reverse transcriptase primer unblocking activity by alpha-phosphate-modified thymidine analogues.
abstract: A dipeptide insertion between codons 69 and 70 together with the amino acid substitution T215Y in the reverse transcriptase (RT)-coding region of human immunodeficiency virus type 1 (HIV-1) strains are known to confer phenotypic resistance to zidovudine (AZT) and stavudine (d4T). Phenotypic resistance correlates with an increased ATP-dependent phosphorolytic activity. Nucleoside alpha-boranophosphate diastereoisomers derived from AZT and d4T were tested as substrates of a multidrug-resistant HIV-1 RT (designated as SS RT) bearing a Ser-Ser insertion at codons 69-70 and other drug resistance-related mutations, in DNA polymerization assays and ATP-mediated excision reactions. Using pre-steady-state kinetics, we show that SS RT can incorporate both R(p) and S(p) diastereoisomers, although R(p) is the preferred isomer. Chirality at the internucleotidic linkage formed upon incorporation of nucleoside alpha-boranophosphate did not affect ATP-mediated excision. As reported for AZT and d4T-terminated primers, substituting Thr, Asn or Ser for Tyr215 abrogates the ATP-dependent phosphorolytic activity on primers terminated with alpha-boranophosphate derivatives of thymidine analogues. However, unlike in the case of AZT, eliminating the dipeptide insertion in SS RT had no effect on the ATP-mediated excision of primers terminated with alpha-boranophosphate derivatives of d4T. Studies with ATP analogues showed that exchanging a non-bridging oxygen atom at the gamma-phosphate group for sulfur causes a significant reduction of the ATP-dependent phosphorolytic activity of SS RT. Interestingly, SS RT's excision activity is completely eliminated upon phosphorothioate substitution at the 3' end of primers terminated with AZT. These results suggest that phosphorothioate derivatives of currently approved drugs could be useful against excision-proficient HIV-1 strains.
authors.affiliation: Centro de Biología Molecular "Severo Ochoa", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, 28049 Madrid, Spain.
authors.forename: Tania
authors.initials: T
authors.lastname: Matamoros
authors.forename: Jérôme
authors.initials: J
authors.lastname: Deval
authors.forename: Catherine
authors.initials: C
authors.lastname: Guerreiro
authors.forename: Laurence
authors.initials: L
authors.lastname: Mulard
authors.forename: Bruno
authors.initials: B
authors.lastname: Canard
authors.forename: Luis
authors.initials: L
authors.lastname: Menéndez-Arias
mesh_terms: D000255:Adenosine Triphosphate / Q000378:metabolism; D001896:Boron Compounds / Q000378:metabolism; D054306:Dideoxynucleotides; D024921:Drug Resistance, Multiple, Viral / Q000502:physiology*; D015497:HIV-1 / Q000201:enzymology / Q000378:metabolism*; D006801:Humans; D007700:Kinetics; D009154:Mutation; D010766:Phosphorylation; D012194:RNA-Directed DNA Polymerase / Q000235:genetics / Q000378:metabolism*; D018119:Stavudine / Q000031:analogs & derivatives; D013936:Thymidine / Q000031:analogs & derivatives* / Q000378:metabolism; D013942:Thymine Nucleotides / Q000378:metabolism; D013997:Time Factors; D015215:Zidovudine / Q000031:analogs & derivatives* / Q000378:metabolism
chemical_list: D001896:Boron Compounds; C415254:Cyclosaligenyl-2',3'-didehydro-2',3'-dideoxythymidine monophosphate; D054306:Dideoxynucleotides; D013942:Thymine Nucleotides; C057287:3'-azido-3'-deoxythymidine 5'phosphate; D015215:Zidovudine; C052873:zidovudine triphosphate; D000255:Adenosine Triphosphate; D018119:Stavudine; D012194:RNA-Directed DNA Polymerase; D013936:Thymidine